Do analysts rate XCUR or KYNB?

Kyntra Bio has a consensus price target of $32.50, suggesting a potential upside of 317.74%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has stronger valuation & earnings, XCUR or KYNB?

Kyntra Bio has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exicure $500K 17.16 -$4.95M -$1.32 N/A Kyntra Bio $6.44M 4.89 $183.45M $45.30 0.17

Is XCUR or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Exicure's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -237.91% -61.98% Kyntra Bio 2,199.13% N/A -47.27%

Do analysts prefer XCUR or QNCX?

Quince Therapeutics has a consensus target price of $260.00, indicating a potential upside of 698.28%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quince Therapeutics 2 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.42

Is XCUR or QNCX more profitable?

Quince Therapeutics' return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -237.91% -61.98% Quince Therapeutics N/A N/A -133.84%

Do analysts rate XCUR or ATNM?

Actinium Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 390.20%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is XCUR or ATNM more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -237.91% -61.98% Actinium Pharmaceuticals N/A -100.85% -47.89%

Do analysts rate ESLA or XCUR?

Estrella Immunopharma currently has a consensus target price of $8.00, suggesting a potential upside of 1,003.45%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Estrella Immunopharma is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ESLA or XCUR more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -328.72% Exicure N/A -237.91% -61.98%

Do analysts prefer XCUR or SGMO?

Sangamo Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75

Is XCUR or SGMO more profitable?

Exicure has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Exicure's return on equity of -237.91% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -237.91% -61.98% Sangamo Therapeutics -310.81% -2,662.06% -132.12%

Exicure (XCUR) Competitors

$1.31 +0.02 (+1.55%)

As of 04:00 PM Eastern

Compare

XCUR vs. KYNB, QNCX, ATNM, ESLA, and SGMO

Should you buy Exicure stock or one of its competitors? Exicure's main competitors and comparable companies include Kyntra Bio (KYNB), Quince Therapeutics (QNCX), Actinium Pharmaceuticals (ATNM), Estrella Immunopharma (ESLA), and Sangamo Therapeutics (SGMO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Exicure compare to Kyntra Bio?

Exicure (NASDAQ:XCUR) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Kyntra Bio has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	17.16	-$4.95M	-$1.32	N/A
Kyntra Bio	$6.44M	4.89	$183.45M	$45.30	0.17

Kyntra Bio has a net margin of 2,199.13% compared to Exicure's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-237.91%	-61.98%
Kyntra Bio	2,199.13%	N/A	-47.27%

In the previous week, Kyntra Bio had 1 more articles in the media than Exicure. MarketBeat recorded 3 mentions for Kyntra Bio and 2 mentions for Exicure. Exicure's average media sentiment score of 1.43 beat Kyntra Bio's score of 0.63 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Positive
Kyntra Bio	Positive

Kyntra Bio has a consensus price target of $32.50, suggesting a potential upside of 317.74%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

42.8% of Exicure shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 52.8% of Exicure shares are held by company insiders. Comparatively, 4.2% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Exicure has a beta of 3.65, meaning that its stock price is 265% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

Summary

Kyntra Bio beats Exicure on 13 of the 17 factors compared between the two stocks.

How does Exicure compare to Quince Therapeutics?

Exicure (NASDAQ:XCUR) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Quince Therapeutics has a consensus target price of $260.00, indicating a potential upside of 698.28%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.42

Quince Therapeutics' return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-237.91%	-61.98%
Quince Therapeutics	N/A	N/A	-133.84%

In the previous week, Quince Therapeutics had 3 more articles in the media than Exicure. MarketBeat recorded 5 mentions for Quince Therapeutics and 2 mentions for Exicure. Exicure's average media sentiment score of 1.43 beat Quince Therapeutics' score of 0.93 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Positive
Quince Therapeutics	Positive

Exicure has higher revenue and earnings than Quince Therapeutics. Exicure is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	17.16	-$4.95M	-$1.32	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A

42.8% of Exicure shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 52.8% of Exicure shares are held by insiders. Comparatively, 7.1% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Exicure has a beta of 3.65, indicating that its share price is 265% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

Summary

Exicure beats Quince Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Exicure compare to Actinium Pharmaceuticals?

Exicure (NASDAQ:XCUR) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Actinium Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 390.20%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Exicure has a beta of 3.65, meaning that its stock price is 265% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

Exicure has higher earnings, but lower revenue than Actinium Pharmaceuticals. Exicure is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	17.16	-$4.95M	-$1.32	N/A
Actinium Pharmaceuticals	$35.09M	0.91	-$48.82M	$0.36	2.83

42.8% of Exicure shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Exicure had 2 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for Exicure and 0 mentions for Actinium Pharmaceuticals. Exicure's average media sentiment score of 1.43 beat Actinium Pharmaceuticals' score of 0.00 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Positive
Actinium Pharmaceuticals	Neutral

Actinium Pharmaceuticals' return on equity of -100.85% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-237.91%	-61.98%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Summary

Actinium Pharmaceuticals beats Exicure on 8 of the 15 factors compared between the two stocks.

How does Exicure compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and Exicure (NASDAQ:XCUR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Estrella Immunopharma's return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-328.72%
Exicure	N/A	-237.91%	-61.98%

Estrella Immunopharma currently has a consensus target price of $8.00, suggesting a potential upside of 1,003.45%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Estrella Immunopharma is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 5.8% of Estrella Immunopharma shares are held by insiders. Comparatively, 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Exicure has higher revenue and earnings than Estrella Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A
Exicure	$500K	17.16	-$4.95M	-$1.32	N/A

Estrella Immunopharma has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Exicure has a beta of 3.65, suggesting that its stock price is 265% more volatile than the broader market.

In the previous week, Estrella Immunopharma had 1 more articles in the media than Exicure. MarketBeat recorded 3 mentions for Estrella Immunopharma and 2 mentions for Exicure. Exicure's average media sentiment score of 1.43 beat Estrella Immunopharma's score of 0.63 indicating that Exicure is being referred to more favorably in the news media.

Company	Overall Sentiment
Estrella Immunopharma	Positive
Exicure	Positive

Summary

Exicure beats Estrella Immunopharma on 8 of the 14 factors compared between the two stocks.

How does Exicure compare to Sangamo Therapeutics?

Exicure (NASDAQ:XCUR) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Exicure has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Exicure's return on equity of -237.91% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-237.91%	-61.98%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Exicure has a beta of 3.65, indicating that its share price is 265% more volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

Sangamo Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

42.8% of Exicure shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 52.8% of Exicure shares are held by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Exicure has higher earnings, but lower revenue than Sangamo Therapeutics. Exicure is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	17.16	-$4.95M	-$1.32	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

In the previous week, Exicure had 2 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 2 mentions for Exicure and 0 mentions for Sangamo Therapeutics. Exicure's average media sentiment score of 1.43 beat Sangamo Therapeutics' score of 0.00 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Positive
Sangamo Therapeutics	Neutral

Summary

Exicure beats Sangamo Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Exicure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XCUR vs. The Competition

Export

Metric	Exicure	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.58M	$3.92B	$7.12B	$12.85B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-0.99	11.69	272.89	25.51
Price / Sales	17.16	1,396.48	686.41	123.12
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	2.11	16.81	11.06	6.34
Net Income	-$4.95M	-$22.71M	$3.47B	$349.45M
7 Day Performance	13.91%	2.89%	1.28%	-0.10%
1 Month Performance	-18.13%	13.06%	8.29%	4.36%
1 Year Performance	-76.63%	55.07%	24.29%	14.91%

Exicure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XCUR Exicure	1.1884 of 5 stars	$1.31 +1.6%	N/A	-77.0%	$8.58M	$500K	N/A	50	Positive News Short Interest Decrease
KYNB Kyntra Bio	2.9582 of 5 stars	$8.10 flat	$32.50 +301.2%	N/A	$32.81M	$6.44M	0.18	570	News Coverage
QNCX Quince Therapeutics	2.7681 of 5 stars	$31.31 +1.2%	$260.00 +730.4%	-89.5%	$31.94M	N/A	N/A	60	News Coverage
ATNM Actinium Pharmaceuticals	1.8646 of 5 stars	$1.01 -6.5%	$5.00 +395.0%	-43.3%	$31.76M	$35.09M	N/A	30
ESLA Estrella Immunopharma	1.7704 of 5 stars	$0.73 -0.3%	$8.00 +995.9%	-32.8%	$31.76M	N/A	N/A	N/A	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XCUR) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exicure (XCUR) Competitors

XCUR vs. KYNB, QNCX, ATNM, ESLA, and SGMO

How does Exicure compare to Kyntra Bio?

Summary

How does Exicure compare to Quince Therapeutics?

Summary

How does Exicure compare to Actinium Pharmaceuticals?

Summary

How does Exicure compare to Estrella Immunopharma?

Summary

How does Exicure compare to Sangamo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exicure (XCUR) Competitors

XCUR vs. KYNB, QNCX, ATNM, ESLA, and SGMO

How does Exicure compare to Kyntra Bio?

Which has stronger valuation & earnings, XCUR or KYNB?

Is XCUR or KYNB more profitable?

Does the media favor XCUR or KYNB?

Do analysts rate XCUR or KYNB?

Do institutionals and insiders hold more shares of XCUR or KYNB?

Which has more risk & volatility, XCUR or KYNB?

Summary

How does Exicure compare to Quince Therapeutics?

Do analysts prefer XCUR or QNCX?

Is XCUR or QNCX more profitable?

Does the media favor XCUR or QNCX?

Which has higher valuation and earnings, XCUR or QNCX?

Do institutionals and insiders believe in XCUR or QNCX?

Which has more risk and volatility, XCUR or QNCX?

Summary

How does Exicure compare to Actinium Pharmaceuticals?

Do analysts rate XCUR or ATNM?

Which has more volatility & risk, XCUR or ATNM?

Which has higher valuation & earnings, XCUR or ATNM?

Do insiders & institutionals believe in XCUR or ATNM?

Does the media prefer XCUR or ATNM?

Is XCUR or ATNM more profitable?

Summary

How does Exicure compare to Estrella Immunopharma?

Is ESLA or XCUR more profitable?

Do analysts rate ESLA or XCUR?

Do institutionals and insiders hold more shares of ESLA or XCUR?

Which has stronger valuation and earnings, ESLA or XCUR?

Which has more volatility & risk, ESLA or XCUR?

Does the media prefer ESLA or XCUR?

Summary

How does Exicure compare to Sangamo Therapeutics?

Is XCUR or SGMO more profitable?

Which has more volatility & risk, XCUR or SGMO?

Do analysts prefer XCUR or SGMO?

Do institutionals & insiders have more ownership in XCUR or SGMO?

Which has higher valuation & earnings, XCUR or SGMO?

Does the media favor XCUR or SGMO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XCUR vs. The Competition

Exicure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools